Cellmid Limited

Receive alerts
Market Cap:
$18.39 m
52 weeks high
52 weeks low

Filter by article type

Viewing results 1-25 of 190


Cellmid to receive EU patent for midkine antibody for cancer, autoimmunity and inflammation

The clinical development milestone adds value to a midkine patent portfolio open to partnering....

3 weeks, 5 days ago

Cellmid Limited outlines key components for FY2020 growth strategy

Cellmid Limited outlines key components for FY2020 growth strategy ...

on 14/8/19

Cellmid subsidiary Advangen International enters into agreement with K2B Co Ltd for distribution of évolis products

Avangen is engaged in the development and sale of clinically validated anti-ageing products for skin, hair and body. ...

on 6/8/19

Cellmid's Japanese shopping channel sale sets revenue record of $1.14 million

Advangen is the company’s wholly-owned subsidiary engaged in development and sale of first in class, best in class clinically validated anti-ageing products. ...

on 4/7/19

Cellmid MD and CEO demonstrates confidence through further on-market share purchase

Maria Halasz has recently lifted her total holding to almost 2.2 million shares through acquiring a further 12,000 shares....

on 11/6/19

Cellmid appoints new Lyramid CEO to drive clinical development of midkine assets

The new CEO’s mandate is to accelerate partnering discussions and explore opportunities to fully exploit the midkine assets....

on 28/5/19

Cellmid managing director and CEO lifts holding in life sciences company with on-market purchase

The company told Proactive Investors in February that it remained on track for record revenues in financial year 2019, targeting profitability in financial year 2020....

on 6/5/19

Cellmid’s évolis Professional product range to be sold in Europe

The évolis® professional products can now be imported into EU countries and the UK following comprehensive safety and compliance reviews. ...

on 30/4/19

Cellmid alopecia patent granted in Europe for évolis® hair therapy

Notification of the intention to grant a patent will increase the commercial value of the évolis® brand beyond sales....

on 2/4/19
Retail & consumer

Cellmid demonstrates strong operational performance with revenue up to $3.6 million in first half FY19

The company has entered the 2019 calendar year in a strong position with a focus on pursuing sales channels that are most profitable, such as Japan. ...

on 21/2/19

Cellmid has significant new findings on midkine published in leading medical journal

Recently published study findings show Cellmid’s midkine antibodies prevented heart muscle damage and preserved function....

on 7/2/19

Cellmid becomes profitable in December after achieving record quarterly sales

The company continued its sales growth trajectory while substantially reducing its debt....

on 23/1/19

Cellmid driving towards profitability with anti-ageing product range

The company sells clinically validated anti-ageing products for hair, skin and body....

on 11/1/19

Cellmid expecting record sales in December quarter, shares up 15%

The company sells anti-ageing products for hair, skin and body....

on 12/12/18

Cellmid partners with NZ pharmacies to distribute anti-ageing products

The first commercial shipment is expected to arrive this month....

on 19/11/18

Cellmid builds IP for midkine portfolio with new patents

The company's patent portfolio comprises 60 patents and applications in 13 patent families....

on 7/11/18

Cellmid launches évolis® Professional products in 17 store locations across the US

Cellmid is now focused on implementing a cost-effective experiential marketing solution....

on 1/11/18

Cellmid banks research and development tax incentive

Cellmid’s consumer health segment generates revenue by selling anti-ageing functional cosmetics and consumer health products....

on 30/10/18

Cellmid director shows faith in life sciences company through on-market trades

Bruce Gordon has acquired two batches of shares recently with a total value of almost $13,300....

on 25/9/18

Cellmid gains new substantial shareholder as director increases his interest to 6.4%

US-based Dennis Eck recently purchased a $1 million parcel of shares and now holds more than 5.331 million....

on 14/9/18

Cellmid board members hoover up company stock

Non-executive director Dennis Eck purchased $1 million worth of stock for 38 cents....

on 13/9/18

Cellmid’s study confirms effectiveness of lead antibody against rare chronic kidney disease

Cellmid can now apply to the US FDA and European EMA for Orphan Drug Designation for CAB102....

on 12/9/18

Cellmid closes share purchase plan after crossing target amount

The offer was at the same price as the recent share placement to sophisticated and institutional investors for $9 million....

on 3/9/18